Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Axert - labeled renal guidance
Product / population
Almotriptan (Axert), oral tablets for acute migraine in adults
Renal method
Clinical renal category or population named in the cited section
Source revision
DailyMed SPL version 2, effective 2012-10-10; posted Oct 25, 2012
DailyMed / product prescribing information · Almotriptan (Axert), oral tablets for acute migraine in adults
Renal method: Clinical renal category or population named in the cited section Source date: DailyMed SPL version 2, effective 2012-10-10; posted Oct 25, 2012 Retrieved: 2026-11-07
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
For severe renal impairment start with 6.25 mg. Limit the total to 12.5 mg in 24 hours. The selected dosing paragraph uses a severity category. Verify full acute-migraine dosing and contraindications.
RDM73-axert-official-1 · Source locator: Renal guidance: 2.3 and 8.7
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
